| 12:30 |
ORAL COMMUNICATION SESSION
Industry research
Chairs: David Lillicrap (Canada), Elena Santagostino (Italy) |
|
Emicizumab prophylaxis in
adolescent/adult patients with haemophilia A previously receiving
episodic or prophylactic bypassing agent treatment: updated analyses
from the HAVEN 1 Study.
Maria Elisa Mancuso (Italy) |
|
Role of rFVIIIFc in immune tolerance induction in severe hemophilia A patients with Inhibitors
Nisha Jain (USA) |
|
Efficacy, safety, and
pharmacokinetics of once-weekly emicizumab prophylaxis in paediatric
persons with haemophilia A (PwHA) with inhibitors two years old or
younger in the HAVEN 2 Study
Flora Peyvandi (Italy) |
|
Low immunogenicity of human-cell-derived recombinant FVIII in previously untreated patients with non-null F8 mutations
Anna Pavlova (Germany) |
|
Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia
Torben Colberg (USA) |
|
Real-World safety and benefit of
early treatment with room temperature-stable recombinant activated
Factor VII (rFVIIa) in patients with haemophilia A or B with inhibitors:
SMART-7™ study results
Kaan Kavakli (Turkey), on behalf of the SMART-7™ steering committee |
